ArticleInternational journal of cardiology. Heart & vasculature2026
Time trends in ICD recommendations and predictors of device activation hypertrophic cardiomyopathy: a real-world cohort study.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sudden cardiac death (SCD) remains a major concern in hypertrophic cardiomyopathy (HCM). Over recent years, European Society of Cardiology (ESC) guidelines have broadened recommendations for implantable cardioverter defibrillator (ICD) implantation in primary prevention. We aimed to evaluate clinical outcomes and event detection in an HCM primary prevention cohort, while assessing how these evolving criteria translate into real-world ICD eligibility and event detection. Methods: We conducted a single-centre retrospective study including 52 consecutive HCM patients who received an ICD for primary prevention between 2014 and 2024. Baseline clinical, imaging, and follow-up data were collected. The primary endpoint was appropriate ICD therapy for ventricular tachycardia or fibrillation. Patients were classified according to the 2014, 2022, and 2023 ESC guidelines. Time-to-event analyses using univariate Cox regression were performed to identify predictors of ICD activation. Results: Over a median follow-up of 2.2 years, 6 patients (12%) experienced appropriate ICD therapy. According to ESC classifications, the 2022/2023 guidelines would have increased ICD eligibility by about 50% compared with the 2014 guideline, mainly due to the inclusion of extensive late gadolinium enhancement on CMR and reduced LVEF (<50%) as risk enhancers. However, no guideline set identified all patients who developed ventricular arrhythmias, and a subset of patients with events would not have been eligible for ICD implantation under any ESC recommendation. Lower LVEF was associated with higher risk of ICD activation. Conclusions: Successive ESC guidelines have lowered the threshold for ICD implantation in HCM, increasing eligibility but also implantations in event-free patients. Persistent event occurrence in ineligible individuals highlights the need for refined prediction models and individualized clinical judgment, including complementary tools such as ILR monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.